PDE4D

3',5'-cyclic-AMP phosphodiesterase 4D · Q08499 · PDE4D on Sugi Atlas →

478,241 patent compounds predicted against PDE4D, 296,605 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cilomilast (SCHEMBL26372)	1.00	19/20
Cilomilast (SCHEMBL27515)	1.00	19/20
Cilomilast (SCHEMBL27516)	1.00	19/20
Roflumilast (SCHEMBL19158)	1.00	18/20
Piclamilast (SCHEMBL26573)	1.00	16/20
Cipamfylline (SCHEMBL26990)	1.00	13/20
Rolipram (SCHEMBL27930)	1.00	11/20
Theophylline Anhydrous (SCHEMBL4915)	0.96	9/20
Theophylline Anhydrous (SCHEMBL5037)	0.81	9/20
SCHEMBL18250	0.56	7/20
Zardaverine (SCHEMBL13334)	1.00	6/20
SCHEMBL29488	0.45	6/20
SCHEMBL20867	0.51	5/20
SCHEMBL18247	0.47	5/20
SCHEMBL20866	0.40	5/20
1-Methylxanthine (SCHEMBL10996)	0.64	4/20
Guaifenesin (SCHEMBL20358)	0.52	4/20
Iodoquinol (SCHEMBL3460)	0.51	4/20
SCHEMBL28454	0.40	4/20
Pitavastatin (SCHEMBL3369)	1.00	3/20

Clinical trials — most relevant to PDE4D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis	PHASE4	COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes	PHASE4	COMPLETED
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage	PHASE3	NOT_YET_RECRUITING
Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes	PHASE3	RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial	PHASE2	COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients	PHASE1/PHASE2	COMPLETED
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients	PHASE1/PHASE2	COMPLETED
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary	PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET	PHASE1	RECRUITING
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.	nan	UNKNOWN
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones	nan	COMPLETED
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children	nan	COMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PDE4D binder may also engage these)

Protein	Name	Similarity
P14270	—	1.000	P14270 →
P14646	—	1.000	P14646 →
PDE4B	3',5'-cyclic-AMP phosphodiesterase 4B	1.000	landscape →
Q01063	—	0.999	Q01063 →
O89084	—	0.998	O89084 →
P54748	—	0.996	P54748 →
PDE4A	3',5'-cyclic-AMP phosphodiesterase 4A	0.995	landscape →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.994	landscape →
PDE4C	3',5'-cyclic-AMP phosphodiesterase 4C	0.994	landscape →
Q63553	—	0.992	Q63553 →
Q92539	—	0.992	Q92539 →
A7MBB4	—	0.992	A7MBB4 →
F4JZ68	—	0.992	F4JZ68 →
A6NIR3	—	0.991	A6NIR3 →
Q2NKQ1	—	0.991	Q2NKQ1 →
Q17QK1	—	0.991	Q17QK1 →
Q1LYM3	—	0.991	Q1LYM3 →
Q9H329	—	0.991	Q9H329 →
P46200	—	0.991	P46200 →
P30645	—	0.991	P30645 →
P06537	—	0.990	P06537 →
Q9XYB7	—	0.990	Q9XYB7 →
Q6EEF3	—	0.990	Q6EEF3 →
Q6NRL1	—	0.990	Q6NRL1 →
Q6ZUT3	—	0.990	Q6ZUT3 →
Q811P8	—	0.990	Q811P8 →
Q5VUJ5	—	0.990	Q5VUJ5 →
Q9Z1T6	—	0.990	Q9Z1T6 →
Q5VW22	—	0.990	Q5VW22 →
SNRK	SNF-related serine/threonine-protein kinase	0.989	landscape →